Ocumension Therapeutics (01477.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 5.35

From 52W high−48.27%

Volume436118.00

Market capHKD 4.18B

P/E (TTM)—

P/S (TTM)3.8x

Div yield—

Key dataSep 18, 2026

Open

HKD 5.35

From 52W high

−48.27%

Volume

436118.00

Market cap

HKD 4.18B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−62.6x

P/E (TTM)

—

RSI (14)

42.9

MomentumView details →

1D Return

−4.77%

YTD Return

−31.15%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−62.6x

EV/Sales

3.9x

P/S (TTM)

3.8x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

47.21%

Net Margin

−13.38%

EBITDA Margin

−6.18%

ROE (TTM)

−3.43%

ROA (TTM)

−3.01%

Asset Turnover

0.23x

GrowthView details →

Revenue YoY

+70.71%

EPS YoY

+53.52%

FCF YoY

−83.86%

Revenue CAGR 3Y

+71.68%

EPS CAGR 3Y

+48.72%

EBITDA YoY

+71.17%

MomentumView details →

1D Return

−4.77%

YTD Return

−31.15%

1Y Return

−42.49%

RSI (14)

42.9

vs 50D SMA

−5.15%

vs 200D SMA

−22.36%

Capital & dividendView details →

Debt/Equity

0.08x

Current Ratio

3.31x

Quick Ratio

3.09x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.14

EPS Surprise

−299.97%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−299.97%

Rev Surprise

−10.32%

Financials snapshotView financials →

Revenue (TTM)

1.47B

Net Income (TTM)

−373.40M

Op. CF (TTM)

−169.73M

Next earningsMar 19, 2027 →

Latest newsMore news →

Ocumension Therapeutics announced that China's National Medical Products Administration Center for Drug Evaluation accepted its new drug application for OT-301 (NCX 470, bimatoprost) for lowering intraocular pressure in open-angle glaucoma or ocular hypertension.10d ago

Ocumension Therapeutics announced that the Phase III clinical trial of OT-211 (TRYPTYR acotiamide eye drops) in China has completed enrollment of 398 patients.18d ago

Similar companies

Amylyx Pharmaceuticals, Inc.AMLX Relay Therapeutics, Inc.RLAY AbCellera Biologics Inc.ABCL Telix Pharmaceuticals LimitedTLX Jacobio Pharmaceuticals Group Co., Ltd.01167.HK 华恒生物688639.SH Find similar companies →

Latest newsMore news →

Ocumension Therapeutics announced that China's National Medical Products Administration Center for Drug Evaluation accepted its new drug application for OT-301 (NCX 470, bimatoprost) for lowering intraocular pressure in open-angle glaucoma or ocular hypertension.10d ago Ocumension Therapeutics announced that the Phase III clinical trial of OT-211 (TRYPTYR acotiamide eye drops) in China has completed enrollment of 398 patients.18d ago Ocumension Therapeutics announced that the first patient has been enrolled in the Phase III clinical trial of OT-202 for dry eye disease in China.20d ago